Navigation Links
Creabilis Appoints Dr David Roblin as Chief Medical Officer
Date:8/4/2011

LUXEMBOURG, August 4, 2011 /PRNewswire/ --

 

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, announces today that Dr David Roblin has been appointed Chief Medical Officer.

Dr Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years and which has seen him deliver several drugs to the market. He has held leadership roles in Pfizer and Bayer across a wide range of therapy areas in research, development and commercial roles. At Pfizer, Dr Roblin was most recently Senior Vice President, Head of Research and Site Head for European R&D. Before joining Pfizer as Head of the Company's European Clinical Research and Development organisation, Dr Roblin held the position of Head of Anti-Infectives at Bayer Medical Affairs. Dr Roblin previously practiced medicine and is a Fellow of the Royal College of Physicians and Member of the Faculty of Pharmaceutical Physicians.  

In addition to Dr Roblin's leadership roles in pharma, he has also chaired the Research Director's Group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a $2bn public-private partnership with the European Commission. He is currently an advisor at NOCRI in the NHS, a non-executive director of Xceleron and an advisor to a number of venture funds.

Dr David Roblin, commenting on his appointment, said: "Creabilis has reached an exciting time in its development with its lead drug candidate, CT327, recently having demonstrated promising Phase IIa results in both psoriasis and atopic dermatitis, with ongoing studies in pain. I look forward to working with the Company as it progresses CT327 and its pipeline of potential new medicines for significant inflammatory and autoimmune conditions."

Dr Eliot Forster CEO of Creabilis sai
'/>"/>

SOURCE Creabilis SA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science
2. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
3. Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors
4. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
5. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
6. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
7. Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO
8. AquaStar Holdings, Inc. Subsidiary Appoints Former Beckman Coulter Executive as Vice President of Operations
9. Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
10. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
11. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... While administrative claims and other ... for a relatively long period of time, there ... use of these ‘big data’ for comparisons of ... today’s powerful computer technology with the plethora of ... holds significant promise for identifying optimal interventions for ...
(Date:7/30/2014)... With the accelerated aging of ... expenditure as well as the improved medical care ... reagent industry has been developing quickly, especially in ... Chinese in vitro diagnostics market size reached RMB22.98 ... vitro diagnostic reagents. , Read complete report ...
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... --  Epic Sciences, Inc. ("Epic"), a private biotech ... and advance the treatment and management of cancer, announced ... as chairman of Epic,s board of directors. Mr. Lucier ... Invitrogen). Mr. Lucier joins Epic,s board of directors to ... analysis platform with special focus on the development of ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... Senomyx, Inc.,(Nasdaq: SNMX ) will release its ... before the opening of the U.S. financial,markets. The Company ... Internet,broadcast that will provide a business update and a ... at 11:00 a.m. Eastern Time (8:00 a.m.,Pacific Time)., ...
... Oct. 20 GeoVax Labs, Inc. (OTC,Bulletin Board: ... for diseases caused by HIV-1 (Human Immunodeficiency Virus),and ... both DNA and,MVA components of its AIDS vaccine ... use in the upcoming Phase 2a human clinical ...
... with Industry to Educate,Promote PRV Program-, WASHINGTON, ... today announced its support of the US Food ... Industry on Priority,Review Vouchers. The Priority Review Voucher ... the development of drugs and vaccines for,neglected tropical ...
Cached Biology Technology:SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 3FDA Issues Draft Guidance on Priority Review Vouchers 2
(Date:7/30/2014)... CHAMPAIGN, Ill. Scientists are searching through a massive ... more than 50 years ago, and the effort is ... world they inhabited. , When the collection is fully ... will be the largest unbiased Dominican amber collection in ... most striking discovery thus far is that of a ...
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
(Date:7/30/2014)... of the roughly 3,000 pieces is still in its ... results will be of major significance. "Amazingly often, we ... in Fushun amber that we found in Baltic amber," ... The Baltic amber comes from the Baltic Sea region, ... in finds are, e.g., the coastal regions of Mecklenburg, ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Chinese mosquitos on the Baltic Sea 2
... October 23, 2013 A promising technique for treating ... may lead to new treatments to prevent blindness, according to ... Jolla, California. The studies involved controlling the actions ... to be "junk" but are now known to fine-tune gene ...
... have found out which molecular mechanisms decide about the ... for the import of proteins into specific cell components, ... receptor remains active or is broken down after the ... regulation of the protein import into peroxisomes has been ...
... simply cannot do without lasers. We use them to print ... car components, survey roads, monitor our bloodstream, and even remove ... for Applied Solid State Physics IAF in Freiburg have developed ... a particular type of infrared laser forms the ...
Cached Biology News:New eye treatment effective in laboratory tests 2New eye treatment effective in laboratory tests 3New eye treatment effective in laboratory tests 4The yin and yang in the life of proteins 2Lasers offer an automated way to test drinking water 2Lasers offer an automated way to test drinking water 3
... The PROTEAN II XL cell, wide format, is used ... x 20 cm gels and requires 1.2 L of ... unit and the 2.0 mm IPG conversion kit, which ... and includes 2 sets of IPG clamps, 2 sets ...
... been developed with the drug discovery process ... sensitivity and performance, Safire is the ideal ... development and high throughput screening. Safire is ... that offers a range of high speed ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
Biology Products: